Uricase Inhibitors
1 drugsAbout Uricase
Uricase, or urate oxidase, is an enzyme that catalyzes uric acid oxidation into allantoin, crucial for purine metabolism in many species but absent in humans. This conversion facilitates uric acid excretion by transforming it into the more soluble allantoin.
The absence of functional uricase in humans leads to hyperuricemia and gout, making it a therapeutic target for managing these conditions. Currently, there is no genetic evidence available to support uricase as a drug target.
Uricase is targeted by one FDA-approved biologic drug, KRYSTEXXA, developed by Horizon Pharma, for gout treatment. Further research could expand therapeutic options in this area.
Top Uricase Drugs
Horizon Pharma is the only company with an approved drug targeting uricase.
High market concentration suggests significant entry barriers or limited investment in this target.
Uricase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Uricase, using enzyme modality.
The absence of small molecule or antibody drugs indicates a whitespace opportunity for novel modalities.
Uricase Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Uricase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 4 | 0 | 0 | 100% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 8 | 8 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Uricase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Uricase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Uricase Drug Approval Timeline (2010 - 2010)
The first and only drug, KRYSTEXXA, was approved in 2010.
The lack of recent approvals suggests potential saturation or challenges in developing new uricase-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Uricase. A trial counts if an approved drug acting on Uricase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.